Celgene

86 Morris Ave , Summit, NJ 07901

Public
Healthcare & Pharmaceuticals - Biotechnology
over $1B
over 10K
(908) 673-9000
(302) 655-5049
information@celgene.com


Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITAL... (Source: SEC reports)


Competitor - 1/9
Which company is more competitive with Celgene?




954 Contacts at this company
Wailing Poon
Associate Director, Global Risk Management ...
Kimberly Hodges
Sr. Product Manager AML Marketing ...
Cricket Hock
Associate Director, Global Hem Analytics ...
Colleen Greenberg
Associate Director, HR Governance
Alex Padilla
Associate Director, Global Quality ...
Bitao Liang
Sr. Director, Product Science, CAR T CMC
Jill Gardi
Director, Myeloid Global Marketing
Ed Bishop
Director, Analytical Development
Y-J Xue
Senior Manager

Sep 12, 2018 17:30:52
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced the results of two post hoc sub-analyses of clinical [...]

Jul 10, 2018 19:24:21
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the Phase III IMpassion130 study, which was sponsored [...]

Jul 10, 2018 17:30:42
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the Phase III IMpassion130 study, which was sponsored [...]

Jun 3, 2018 18:54:37
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced additional results from RELEVANCE, a phase III, randomized, open-label, international clinical [...]

Jun 3, 2018 17:31:02
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced additional results from RELEVANCE, a phase III, randomized, open-label, international clinical [...]

Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.